Ixekizumab vs Secukinumab — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Interleukin-17A Antagonist

Ixekizumab

Brand: TALTZ

First FDA approval: 2016-03-22

Interleukin-17A Antagonist

Secukinumab

Brand: COSENTYX

First FDA approval: 2015-01-21

Lowest NADACAcquisition cost floor across all NDCs

$7347.54Per unit

$3950.77Per unit

Average NADACAcross all dosage forms and strengths

$7391.71Up to $7435.87

$5563.85Up to $7923.31

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$1.04BFull year

$2.59BFull year

Part D claims (CY24)Total fills, all strengths

125K25K beneficiaries

290K55K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$8,363Per claim, all NDCs

$8,926Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

88Minimal friction

1032Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only